| Stereochemistry | RACEMIC |
| Molecular Formula | C16H25NO3 |
| Molecular Weight | 279.3746 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=CC(=C1)[C@]2(O)C[C@@H](O)CC[C@H]2CN(C)C
InChI
InChIKey=LQJLLAOISDVBJM-OFQRWUPVSA-N
InChI=1S/C16H25NO3/c1-17(2)11-13-7-8-14(18)10-16(13,19)12-5-4-6-15(9-12)20-3/h4-6,9,13-14,18-19H,7-8,10-11H2,1-3H3/t13-,14-,16+/m0/s1
| Molecular Formula | C16H25NO3 |
| Molecular Weight | 279.3746 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Axomadol is a centrally active analgesic agent with opioid agonistic properties and with inhibitory effects on the reuptake of the monoamines noradrenaline and, to serotonin [5‐hydroxytrypyamine (5‐HT)]. The drug participated in phase II clinical trials in the treatment of patients with moderate to severe chronic low back pain. As a result, the axomadol didn’t meet predetermined study endpoint, and studies were discontinued.
